NephroDI Therapeutics, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
NephroDI Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2024).
SEC Form D · Jun 2024
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jun 2024
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of NephroDI Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jeff M. Sands, M.D. | Executive officer | Jun 2024 |
| Rachael Hagan | Executive officer | Jun 2024 |
| Bibhash M. Mukhopadhyay | Director | Jun 2024 |
| Michael Grissinger | Director | Jun 2024 |
| Rachael Hagan | Director | Jun 2024 |
| Chris M. Garabedian | Director | Feb 2021 |
| Donna M. See | Director | Feb 2021 |
| Fred M. Callori | Director | Feb 2021 |